AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2017-06, Vol.35 (S2), p.428-428 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 428 |
|---|---|
| container_issue | S2 |
| container_start_page | 428 |
| container_title | Hematological oncology |
| container_volume | 35 |
| creator | Ghia, P. Tam, C.S. Siddiqi, T. Stevens, D. Flinn, I.W. Russell, K. Eckert, K. Zhou, C. Ninomoto, J. James, D.F. Wierda, W.G. |
| description | |
| doi_str_mv | 10.1002/hon.2440_13 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1906625939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1906625939</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1873-cb2e13438719e5403ea09675c7314e533038e5425f41d386dce5cd7c00cb3a0e3</originalsourceid><addsrcrecordid>eNp9kM9OwkAQhzdGExE9-QKbeDSF2d3-PZay0E3KltAF9dSUskQIArYSw8030HfyTXwSNylePU1mft_MJB9CtwQ6BIB2n3fbDrVtyAk7Qy0CQWARcINz1ALq-RZQRi_RVV2vAUwGfgutQ4lTOUyFHOJxHGYcU5ypaf8JpwMsepOpElL0cJSOekLyPn4QKsYzLrlKoyR8xELicagElyprMjXhoRqZ_ufjS4bfnzOOoyTpZklyjS6WxabWN6faRtMBV1FsJelQRGFilcT3mFXOqSbMZr5HAu3YwHQBges5pceIrR3GgPlmTp2lTRbMdxeldsqFVwKUc1aAZm1019zdV7vXg67f8vXuUG3Ny5wE4LrUCVhgqPuGKqtdXVd6me-r1UtRHXNi9BmZuZGZn2QamjX0-2qjj_-heZzKv61faV1uwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1906625939</pqid></control><display><type>article</type><title>AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL</title><source>Wiley Online Library All Journals</source><creator>Ghia, P. ; Tam, C.S. ; Siddiqi, T. ; Stevens, D. ; Flinn, I.W. ; Russell, K. ; Eckert, K. ; Zhou, C. ; Ninomoto, J. ; James, D.F. ; Wierda, W.G.</creator><creatorcontrib>Ghia, P. ; Tam, C.S. ; Siddiqi, T. ; Stevens, D. ; Flinn, I.W. ; Russell, K. ; Eckert, K. ; Zhou, C. ; Ninomoto, J. ; James, D.F. ; Wierda, W.G.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.2440_13</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Chronic lymphocytic leukemia ; Inhibitor drugs ; Patients ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2017-06, Vol.35 (S2), p.428-428</ispartof><rights>2017 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1873-cb2e13438719e5403ea09675c7314e533038e5425f41d386dce5cd7c00cb3a0e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.2440_13$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.2440_13$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids></links><search><creatorcontrib>Ghia, P.</creatorcontrib><creatorcontrib>Tam, C.S.</creatorcontrib><creatorcontrib>Siddiqi, T.</creatorcontrib><creatorcontrib>Stevens, D.</creatorcontrib><creatorcontrib>Flinn, I.W.</creatorcontrib><creatorcontrib>Russell, K.</creatorcontrib><creatorcontrib>Eckert, K.</creatorcontrib><creatorcontrib>Zhou, C.</creatorcontrib><creatorcontrib>Ninomoto, J.</creatorcontrib><creatorcontrib>James, D.F.</creatorcontrib><creatorcontrib>Wierda, W.G.</creatorcontrib><title>AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL</title><title>Hematological oncology</title><subject>Chronic lymphocytic leukemia</subject><subject>Inhibitor drugs</subject><subject>Patients</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kM9OwkAQhzdGExE9-QKbeDSF2d3-PZay0E3KltAF9dSUskQIArYSw8030HfyTXwSNylePU1mft_MJB9CtwQ6BIB2n3fbDrVtyAk7Qy0CQWARcINz1ALq-RZQRi_RVV2vAUwGfgutQ4lTOUyFHOJxHGYcU5ypaf8JpwMsepOpElL0cJSOekLyPn4QKsYzLrlKoyR8xELicagElyprMjXhoRqZ_ufjS4bfnzOOoyTpZklyjS6WxabWN6faRtMBV1FsJelQRGFilcT3mFXOqSbMZr5HAu3YwHQBges5pceIrR3GgPlmTp2lTRbMdxeldsqFVwKUc1aAZm1019zdV7vXg67f8vXuUG3Ny5wE4LrUCVhgqPuGKqtdXVd6me-r1UtRHXNi9BmZuZGZn2QamjX0-2qjj_-heZzKv61faV1uwQ</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Ghia, P.</creator><creator>Tam, C.S.</creator><creator>Siddiqi, T.</creator><creator>Stevens, D.</creator><creator>Flinn, I.W.</creator><creator>Russell, K.</creator><creator>Eckert, K.</creator><creator>Zhou, C.</creator><creator>Ninomoto, J.</creator><creator>James, D.F.</creator><creator>Wierda, W.G.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201706</creationdate><title>AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL</title><author>Ghia, P. ; Tam, C.S. ; Siddiqi, T. ; Stevens, D. ; Flinn, I.W. ; Russell, K. ; Eckert, K. ; Zhou, C. ; Ninomoto, J. ; James, D.F. ; Wierda, W.G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1873-cb2e13438719e5403ea09675c7314e533038e5425f41d386dce5cd7c00cb3a0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Chronic lymphocytic leukemia</topic><topic>Inhibitor drugs</topic><topic>Patients</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghia, P.</creatorcontrib><creatorcontrib>Tam, C.S.</creatorcontrib><creatorcontrib>Siddiqi, T.</creatorcontrib><creatorcontrib>Stevens, D.</creatorcontrib><creatorcontrib>Flinn, I.W.</creatorcontrib><creatorcontrib>Russell, K.</creatorcontrib><creatorcontrib>Eckert, K.</creatorcontrib><creatorcontrib>Zhou, C.</creatorcontrib><creatorcontrib>Ninomoto, J.</creatorcontrib><creatorcontrib>James, D.F.</creatorcontrib><creatorcontrib>Wierda, W.G.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghia, P.</au><au>Tam, C.S.</au><au>Siddiqi, T.</au><au>Stevens, D.</au><au>Flinn, I.W.</au><au>Russell, K.</au><au>Eckert, K.</au><au>Zhou, C.</au><au>Ninomoto, J.</au><au>James, D.F.</au><au>Wierda, W.G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL</atitle><jtitle>Hematological oncology</jtitle><date>2017-06</date><risdate>2017</risdate><volume>35</volume><issue>S2</issue><spage>428</spage><epage>428</epage><pages>428-428</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.2440_13</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2017-06, Vol.35 (S2), p.428-428 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_1906625939 |
| source | Wiley Online Library All Journals |
| subjects | Chronic lymphocytic leukemia Inhibitor drugs Patients Targeted cancer therapy |
| title | AN ONGOING PHASE 2 STUDY OF IBRUTINIB COMBINED WITH VENETOCLAX IN PATIENTS WITH TREATMENT‐NAÏVE CLL/SLL |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A10%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AN%20ONGOING%20PHASE%202%20STUDY%20OF%20IBRUTINIB%20COMBINED%20WITH%20VENETOCLAX%20IN%20PATIENTS%20WITH%20TREATMENT%E2%80%90NA%C3%8FVE%20CLL/SLL&rft.jtitle=Hematological%20oncology&rft.au=Ghia,%20P.&rft.date=2017-06&rft.volume=35&rft.issue=S2&rft.spage=428&rft.epage=428&rft.pages=428-428&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.2440_13&rft_dat=%3Cproquest_cross%3E1906625939%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1906625939&rft_id=info:pmid/&rfr_iscdi=true |